Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Meric

Showing results (21-30 of 68) with videos related to

Pageof 7
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 6, 2020
Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumorsR Bahleda, F Meric-Bernstam, L Goyal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2013
Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapyJ Sohn, K A Do, S Liu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2024
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profilingL Goyal, D DiToro, A Hollebecque, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 10, 2012
Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapyA M Gonzalez-Angulo, S Liu, H Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 11, 2012
Multifocality and multicentricity in breast cancer and survival outcomesS P Lynch, X Lei, M Chavez-MacGregor, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 25, 2009
Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implicationsN Cabioglu, A A Sahin, P Morandi, et al.
Cancer|September 26, 2001
Breast conservation therapy as a treatment option for the elderly. The M. D. Anderson experienceG Vlastos, N Q Mirza, F Meric, et al.
ESMO Open|December 23, 2021
Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanomaM A Gouda, J Polivka, H J Huang, et al.
Breast Cancer Research and Treatment|November 6, 2004
Expression of sigma 1 receptor in human breast cancerB Wang, R Rouzier, C T Albarracin, et al.
Annals of Surgical Oncology|January 5, 2002
Utility of breast sentinel lymph node biopsy using day-before-surgery injection of high-dose 99mTc-labeled sulfur colloidC C Solorzano, M I Ross, E Delpassand, et al.
Pageof 7

Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 6, 2020
Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumorsR Bahleda, F Meric-Bernstam, L Goyal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2013
Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapyJ Sohn, K A Do, S Liu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2024
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profilingL Goyal, D DiToro, A Hollebecque, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 10, 2012
Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapyA M Gonzalez-Angulo, S Liu, H Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 11, 2012
Multifocality and multicentricity in breast cancer and survival outcomesS P Lynch, X Lei, M Chavez-MacGregor, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 25, 2009
Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implicationsN Cabioglu, A A Sahin, P Morandi, et al.
Cancer|September 26, 2001
Breast conservation therapy as a treatment option for the elderly. The M. D. Anderson experienceG Vlastos, N Q Mirza, F Meric, et al.
ESMO Open|December 23, 2021
Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanomaM A Gouda, J Polivka, H J Huang, et al.
Breast Cancer Research and Treatment|November 6, 2004
Expression of sigma 1 receptor in human breast cancerB Wang, R Rouzier, C T Albarracin, et al.
Annals of Surgical Oncology|January 5, 2002
Utility of breast sentinel lymph node biopsy using day-before-surgery injection of high-dose 99mTc-labeled sulfur colloidC C Solorzano, M I Ross, E Delpassand, et al.
Pageof 7